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Daptomycinis a lipopeptide antibioticwitha unique mechanism ofactiononGram-positive bacteria. It is approved fortreatment
of skin and soft-tissue infections with Gram-positive bacteria, bacteraemia and right-sided infective endocarditis caused by
Staphylococcus aureus. Diminishing susceptibility of S. aureus to daptomycin during treatment of complicated infections and
clinical failure have been described. Combinations of daptomycin with other antibiotics including gentamicin, rifampin, beta-
lactams, trimethoprim/sulfamethoxazole(TMP-SMX), or clarithromycin present a new approach for therapy. In vitro and animal
studies have shown that such combinations may, in some cases, be superior to daptomycin monotherapy. In this paper we focus
on the antibiotic combinations for complicated S. aureus infections.
1.Introduction
Daptomycin, an antibiotic with a new mechanism of action
and low occurrence of spontaneous resistance, came to
market in 2003 in the USA and in 2006 in Europe. In
spite of its many promises for treatment of infections
caused by Gram-positive bacteria, reports on clinical failure
and diminished in vitro susceptibility soon came forward.
Alongside, it became clear that daptomycin monotherapy
of bioﬁlm-related and deep-seated infections is often not
eﬀective. Due to limited clinical settings in which dapto-
mycin is eﬀective, diminishing susceptibility to daptomycin,
emerging resistance to linezolid, and slow development of
new antibiotics, clinicians have diﬃculties treating serious
Staphylococcus aureus infections. Therefore, combinations of
daptomycin with other antibiotics are extensively studied
as a potential new therapeutic strategy. In this review, we
will focus on the antibiotic combinations for complicated S.
aureus infections.
2.DaptomycinPharmacology
Daptomycin is a novel lipopeptide antibiotic approved for
treatment of complicated skin and soft-tissue infections
caused by Gram-positive bacteria, and for S. aureus bacter-
aemia and right-sided endocarditis [1]. It is not active in low
respiratory tract infections, because lung surfactant forms
complexes with daptomycin thereby inactivating it [2].
Daptomycin mechanism of action is complex and not
entirely understood. Research so far indicates that it acts
on cell membrane [3, 4] and also inhibits the synthesis of
lipoteichoic acid, necessary for cell wall synthesis [4].
Daptomycin structure consists of an anionic core and
a lipophilic tail. By binding divalent calcium and forming
Ca2+-complexes, the net charge of the molecule becomes
positive and thus enables electrostatic interactions with
negatively charged cell membrane. It then binds to cell
membrane, where it forms oligomers and subsequently
channels through which intracellular ions, like potassium,
leak out of the cell, diminishing cell membrane negative
potential and causing cell death [3]. This initial model was
later modiﬁed according to the observation that daptomycin
forms micelle-like structures in the medium and bindsto the
membrane in the already oligomerized form [5]. However,
Hobbs et al. found that changes in dissipation of membrane
potential and leakage of intracellular material occur rather
late, after cell death, and with no signiﬁcant alterations in
membraneintegrity[6].Similarly,nosigniﬁcantcelllysiswas2 Chemotherapy Research and Practice
found by electron microscopy and the membrane integrity
probes used on S. aureus treated in vitro with daptomycin
[7]. In addition, analogous to cell wall active antibiotics,
daptomycinwas found to upregulate cell wall stress stimulon
genes[8]. The gene expression proﬁle of S. aureus after being
exposed to daptomycin is similar to proﬁles developed after
exposure to cell wall active antibiotics, such as beta-lactams,
as well as to compounds which disrupt cell membrane,
like carbonyl cyanide m-chlorophenylhydrazone [8]. Thus,
beside acting on the cell membrane, daptomycin likely acts
on several other targets.
Daptomycin activity is sensitive to the inoculum of the
infectious micro-organism [9]. This is probably due to the
decreaseofthelocaleﬀectiveantibioticconcentrationathigh
inoculum [10]. Therefore, suﬃcient serum concentrations
are essential for clearance of bacteria from the infection site.
The current susceptibility cutoﬀ MIC of S. aureus
isolates to daptomycin is set at 1mg/L [11]. In some cases,
susceptibility proﬁle is heterogeneous [12]. No MIC creep
like in the case of vancomycin has been noticed [13–15],
even in the isolates collected over several decades [11]. Since
unequivocal criteria for resistance have not been deﬁned yet,
the term non-susceptibility is used instead of resistance.
3.Mechanisms of Non-susceptibility
to Daptomycin
Strains of S. aureus non-susceptible to daptomycin have
been obtained from clinical cases, by in vitro selection,
and by chemical mutagenesis. Frequency of spontaneous
daptomycin resistance in S. aureus is low (10−10)[ 12]. Serial
passages in subinhibitory concentrations of daptomycin give
rises of MICs by a factor of 8–32; the same is valid for
chemical mutagenesis [12, 16, 17].
Several genes have been implicated in S. aureus non-
susceptibility to daptomycin. Overexpression and mutations
in mprF[ 18–20] which encodes lysyl-phosphatidylglycerol
(LPG) synthetase and ﬂippase, and yycG which encodes
histidine kinase in a two-component sensor regulatory
system of YycF/YycG [16, 20] were identiﬁed in clinical
isolates and laboratory-derived strains, while rpoB[ 20, 21]
and rpoC[ 16] which encode β and β
  subunits of RNA
polymerase were detected only in in vitro selected laboratory
non-susceptible strains. In vitro insertional mutation of
cspB[ 22], a cold shock gene, led to increased susceptibility
to daptomycin in a daptomycin non-susceptible strain of
S. aureus. Several mutants obtained in vitro and some of
the clinical isolates contain at least one of these genetic
changes; a combination of the genetic alterations seems to
have an additive eﬀect on the MIC value [20]. However,
some daptomycin non-susceptible strains do not have any of
these alterations [23, 24], indicating that the mechanism of
“resistance” is probably multifactorial.
The phenotypic alterations in non-susceptible S. aureus
can be grouped into (1) changes in cell wall structure and
turnover;(2)changesinmembrane composition,membrane
structure, and membrane potential; (3) modiﬁcations in
sensitivity todepolarization, autolysis,and permeabilization.
In some cases, thicker cell wall had been correlated to non-
susceptibility [18, 20, 21, 25], but this was not a uniform
ﬁnding; for example, Yang et al. found no changes in cell wall
thickness in a clinical meticillin-resistant S. aureus (MRSA)
isolate with diminished susceptibility to daptomycin which
developed during treatment [19]. S. aureus strains non-
susceptible to daptomycin had an increased synthesis of LPG
and increased translocation of LPG to the outer membrane,
and hence modiﬁcations in membrane ﬂuidity and elec-
trostatic potential [19, 20, 26]. A loss of an unidentiﬁed
81kD membrane protein has also been described in a non-
susceptible clinical isolate [17].
Sofar, most casesofclinicallyacquirednon-susceptibility
of S. aureus to daptomycin occurred in a setting of inade-
quate dosing [17] and/or deep-seated, high-inoculum, and
bioﬁlm-related infective, such as infectious endocarditis (IE)
[17, 19, 26, 27] or bone infections [24]. In these cases,
the eﬀective concentration of daptomycin at the site of the
highest bacterial density is low [10], and activity is further
diminished by the stationary phase of bacteria in bioﬁlm
which has been associated with such infections [28].
4.RelationshipbetweenDiminished
Susceptibilityto
Vancomycinand Daptomycin
Diminished susceptibility of S. aureus to vancomycin has
been associated with a development of diminished sus-
ceptibility to daptomycin. This has been established for
multidrug resistant (MDR) S. aureus,f o rM R S A ,a sw e l la s
for meticillin-susceptible S. aureus (MSSA). Daptomycin is
often prescribed for treatment of MDR S. aureus infections
if vancomycin therapy fails. Clinical experience indicates
that strains of S. aureus with diminished susceptibility to
vancomycin develop a diminished susceptibility to dapto-
mycin during treatment [27, 29–31]o re v e ni na b s e n c e
of daptomycin exposure [32, 33]. Several studies found
that diminished susceptibility to vancomycin in MRSA is
associated with diminished susceptibility to daptomycin
[32], and, according to some reports, that it correlates well
with increased cell wall thickness [25, 27]. The highest
MICs of vancomycin intermediate S. aureus (VISA)/MRSA,
observed in deep-seated infections such as septic arthritis
and osteomyelitis, are often associated with higher MICs for
daptomycin or even with non-susceptibility to daptomycin
[33]. In the case of MRSA IE and septic thrombophlebitis,
the patient’s strain developed non-susceptibility to gly-
copeptides during treatment with glycopeptides, and, after
switching therapy to daptomycin, a non-susceptibility to
daptomycin. MRSA was successfully eradicated from the
bloodstream only after therapy with linezolid and fusidic
acid [27]. A similar relationship was found for MSSA:
diminished susceptibility to vancomycin which developed
during therapy of patients with osteomyelitis [34]o rI E
[26] was associated with a higher MIC to daptomycin
even though the patients had never received it. Subsequent
analysis found that vancomycin and daptomycin exhibited
a reduced bactericidal activity towards the non-susceptibleChemotherapy Research and Practice 3
Table 1: Data on previous vancomycin/daptomycin therapy in MRSA and MSSA clinicalisolates non-susceptible to daptomycin.
Strain Infection
Previous
VAN therapy
(days)
Reason for
change DAP therapy MIC of DNS
strain (days∗) Outcome Ref.
MRSA IE Yes (No data) Failure Yes MIC 2b (No
data) No data [26]( C a s e
report)
MRSA IE Yes (47∗∗)F a i l u r e Y e s M I C 4 a (14) Died (C. albicans septic
shock)
[27]( C a s e
report)
MRSA IE Yes (46∗∗∗)F a i l u r e 6mg/kg
q24h MIC 4a (24) Survived on alternative
treatment
[30]( C a s e
report)
MRSA BSI Yes (15) Failure
6mg/kg
q24h, then
8mg/kg
q24h
MIC 4a (6) Died [31]( C a s e
report)
MRSA BSI Yes (No data) No change No MIC 2a (No
data) No data [32]( C a s e
series)
MRSA UTI Yes (12) Failure 6mg/kg
q24h MIC 4a (7) Died [29]( C a s e
report)
MSSA OM Yes (60) Failure No MIC 4a (No
data)
Survived on alternative
treatment(nafcillin
+rifampin)
[34]( C a s e
report)
DAP: daptomycin; VAN: vancomycin; DNS: daptomycin non-susceptible; UTI: urinary tract infection; BSI: bloodstream infection; IE: infective endocarditis;
OM: osteomyelitis. MRSA: meticillin-resistant S. aureus; MSSA: meticillin-susceptible S. aureus; ∗duration (days) of treatment with daptomycin prior
to isolate was obtained; ∗∗vancomycin for 12 days, then teicoplanin 35 days; ∗∗∗2 courses: 6 weeks initially, additional 4 days after relapse; (a) broth
microdilution (b) Etest. All initial isolates were susceptible to daptomycin; MIC: minimal inhibitory concentration (mg/L).
examined strain and a lesser degree of its chemical autolysis
was observed [34]. Nevertheless, in vitro time-kill studies
show that daptomycin retains bactericidal activity in spite of
increased MIC provided that the concentrations exceed MIC
by several times [31]( Table 1).
However, not all studies conﬁrmed that diminished
susceptibility of S. aureus to vancomycin is associated with
diminished susceptibility to daptomycin. In a retrospective
study of the inﬂuence of previous vancomycin therapy
on MIC and bactericidal activity of daptomycin and van-
comycin in S. aureus (isolates from patients who received
vancomycin within 30 days prior to development of MRSA
bacteraemia were compared with isolates from those who
did not receive the drug), higher MICs and decreased killing
was established only for vancomycin but not for daptomycin
[35].
5.AntibioticCombinationswithDaptomycin
In some groups of patients, such as those infected with
S. aureus strains which have diminished susceptibility to
both vancomycin and daptomycin, especially in the case of
MDR S. aureus, or in patients with deep-seated daptomycin
susceptible S. aureus infections, monotherapy with dapto-
mycin at approved doses (4–6mg/kg/day) is frequently not
eﬀectiveand may even yield non-susceptible isolates. In such
patients, treatment options are highly limited, and addition
of another antibiotic to daptomycin may be beneﬁcial.
The combinations can be divided into three groups: (1)
classical combinations of daptomycin and gentamicin or
rifampicin; (2) combinations of daptomycin and beta-
lactams; (3) combinations of daptomycin with bacteriostatic
antibiotics such as trimethoprim/sulfamethoxazole (TMP-
SMX) or clarithromycin. Findings on in vivo and in vitro
synergy of antibiotic combinations are depicted on Tables 2
and 3.
5.1. Combinations of Daptomycin with
Gentamicin or Rifampin
5.1.1. Infective Endocarditis. Standard treatment of left-sided
IE caused by S. aureus usually includes two antibiotics
with a synergistic bactericidal action, typically a cell wall
synthesis inhibitor and an aminoglycoside, with the addition
of rifampicin in case of infected prosthetic material [36].
Study on a small number of severely ill patients with
left-sided S. aureus endocarditis revealed that daptomycin
monotherapy was inferior to standard therapy, and that both
treatment groups had a very low success rate (11% and 22%,
resp.) [1]. A retrospective analysis of data from daptomycin
outcomes registry [37, 38] suggested that the overall success
of treatment of the left-sided IE caused by S. aureus may be
as high as 60% with the majority of the patients receiving
daptomycin in combination with other antibiotics. These
ﬁndings were a stimulus for the assessment of the eﬃcacy of
daptomycin in combination with other antibiotics, initially
with gentamicin or rifampicin, that is, antibiotics used for
standard treatment.
Combination of daptomycin with gentamicin or
rifampicin was tested in vitro as well as in in vivo
animal models of IE [39]. Etest with MSSA/heterogene-
ous glycopeptide-intermediate S. aureus (hGISA) and
MRSA/GISA showed synergy of daptomycin-gentamicin4 Chemotherapy Research and Practice
Table 2: Information on in vivo synergy of antibiotic combinations.
Model Strain Combination Observation Ref.
Experimental model
of IE MRSA
Daptomycin 6mg/kg q24h + rifampin
300mg q8h
Rifampin and gentamicin
antagonized/delayed the bactericidal
activity of daptomycin
[39]
Daptomycin 6mg/kg q24h + gentamicin
1.3mg/kg q12h
Rabbit model of IE MRSA
Daptomycin 6mg/kg q24h + gentamicin
1mg/kgq8h 60% vegetations sterilized [41]
Daptomycin 6mg/kg q24h + rifampin
300mg q8h 20% vegetations sterilized
Rabbit model of IE DNS MRSA Daptomycin 12mg/kg q24h + oxacillin
200mg/kg q8h Enhanced bacterial clearance from tissues [56]
Case report on IE
MRSA with
progressive loss
of susceptibility
during
treatment
Treated with vancomycin, then
daptomycin 6mg/kg q24h, then
daptomycin 12mg/kg q24h + rifampin
300mg q8h
Clinical success [42]
Rabbit acute
osteomyelitis model MRSA Daptomycin 6mg/kg q24h Failure to eradicate bacteria [50]
Daptomycin 6mg/kg q24h + rifampin
20a mg/kg q12h
Eradication of bacteria: bone 100%, bone
marrow 89%, and joint ﬂuid 44%
Guinea pig
foreign-body
infection model
MRSA
Daptomycin 20mg/kg q24h + rifampin
12.5mg/kg q12h 25% cure [51]
Daptomycin 30b mg/kg q24h + rifampin
12.5mg/kg q12h 67% cure
Vancomycin 15mg/kg q12h + rifampin
12.5mg/kg q12h 8% cure
Rat foreign-body
infection model MRSA
Daptomycin 100c mg/kg q24h +
rifampin 25mg/kg q12h 94% cure [53]
Daptomycin 45mg/kg q24h + rifampin
25mg/kg q12h 64% cure
Vancomycin 50mg/kg q12h +rifampin
25mg/kg q12h 25% cure
In vitro PK/PD model
of SEV DNS MRSA
Daptomycin 6mg/kg q24h + TMP/SMX
160/800mg q12h Bactericidal activity reached at 8 hours [59]
Daptomycin 6mg/kg q24h + cefepime
2gq8h
In vitro PK/PD model
of SEV MSSA, MRSA
Daptomycin6–8mg/kgq24h+
gentamicin 5mg/kg as a single dose; or +
gentamicin 1mg/kg q8h, three doses only
Daptomycin 6–8mg/kg/day combined
with one 5mg/kg dose of gentamicin was
bactericidal in 4h
[66]
In vitro PK/PD model
of SEV GISA, MRSA Daptomycin3–6mg/kgq24h+
arbekacin 100mg q12h
Synergy, but regrowth in 48h in the
regimen with daptomycin4mg/kg/day [67]
Equivalent dosing to (a) rifampin 10mg/kg q12h oral administration (b) daptomycin 6mg/kg q24h (c) daptomycin 10mg/kg q24h in humans; PK/PD:
pharmacokinetic/pharmacodynamic; SEV: simulated endocardial vegetations; TMP/SMX: trimethoprim-sulfamethoxazole; IE: infective endocarditis, DNS:
daptomycin non-susceptible; MRSA: meticillin-resistant S. aureus; GISA: glycopeptide-intermediate S. aureus.
combination for both types of strains used while the
time-kill studies conﬁrmed the synergy only in the case
of MSSA/hGISA [40]. Combinations of daptomycin and
rifampicin were indiﬀerent in both assays [40]. In an in vitro
pharmacodynamic model of IE with simulated endocardial
vegetations and daptomycin susceptible MRSA strain, the
addition of rifampicin and gentamicin substantially delayed
or even antagonized the bactericidal eﬀect of daptomycin
[39]. Similar results were found in an in vivo rabbit model of
aortic IE caused by daptomycin-susceptible MRSA: not only
was the addition of gentamicin or rifampicin to daptomycin
at 6mg/kg/day of no beneﬁcial value, the combination
treatment was less successful in lowering the bacterial cell
counts than daptomycin monotherapy [41].
However, in a clinical case of a mitral valve endocarditis
with heterogeneous population of S. aureus, where one pop-
ulation was fully susceptible to vancomycin and daptomycin
and the other non-susceptible, the addition of rifampicin
to a high dose of daptomycin (12mg/kg/day) resulted in
treatmentsuccesswithsterilebloodculturesin72hours[42].Chemotherapy Research and Practice 5
5.1.2. Bone Infections, Foreign-Body Infections, and Bioﬁlms.
In general, antibiotic combinations with rifampicin more
successfully treat prosthetic devices-related staphylococcal
infections [43, 44]a n dm o r ee ﬃciently eradicate S. aureus
bioﬁlm than monotherapy without rifampicin [45]. Because
penetration ofantistaphylococcal antibiotics into the bioﬁlm
is variable [46]a n dt h eb a c t e r i aa r ei nas e n e s c e n ts t a t e[ 28],
serum concentrations of the anti-staphylococcal drug may
play a role in successful eradication of staphylococci from
ab i o ﬁ l m[ 46]. In addition, activity of several antibiotics,
including daptomycin, is concentration dependent, and thus
enhanced with higher serum concentrations [4]. Penetration
of rifampicin [47] and daptomycin [48]i na nS. epidermidis
bioﬁlm is good, but, in the absence of data, we may only
speculate that the same is valid for S. aureus bioﬁlms.
Information on the eﬃcacy of daptomycin alone and
in combination with rifampicin for treatment of S. aureus
bone and foreign-body infections is rather incomplete,
and limited to in vitro testing and in vivo animal model
investigations; the ﬁndings of the studies are not completely
unequivocal. An in vivo study using a rat model of foreign-
body infection with a fully susceptible MSSA has found that
daptomycin monotherapy at low doses (corresponding to
humandoseof4mg/kg/day)is aseﬀectiveasvancomycinbut
can lead to diminished susceptibility to daptomycin which
developsduring treatment [49]. In an animal model of acute
osteomyelitis caused by MRSA susceptible to vancomycin,
daptomycin, and rifampicin, monotherapy with daptomycin
(6mg/kg/day) was not successful and in some cases dimin-
ished susceptibility occurred during therapy. Addition of
rifampicin resultedinamorefrequenteradicationofbacteria
from the bone and prevented the emergence of resistant
strains [50]. Similarly, in a guinea pig foreign-body infection
model with MRSA susceptible to daptomycin, the addi-
tion of rifampicin to an intermediate dose of daptomycin
(6mg/kg/day) resulted in treatment success in two thirds
of the animals whereas monotherapy was ineﬀective [51].
Higher doses of daptomycin seem to be better in eradicating
thebacteria,butcombinationswithrifampicinareevenmore
eﬃcient. A comparison of daptomycin (corresponding to
human dose of 10mg/kg/day) and rifampicin monotherapy
in a rat model of foreign-body infection with MRSA
susceptible to daptomycin and rifampicin has shown that
both therapies are equally eﬀective, but rifampicin resis-
tance developed during treatment in 60% [52]. In a rat
model of foreign-body infection with MRSA susceptible
to vancomycin, daptomycin, and rifampicin, monotherapy
with a high dose of daptomycin (10mg/kg/day) eﬀectively
decreasedbacterialcellcounts(over3logCFU/mlbyday11);
the combination of high-dose daptomycin and rifampicin
was even more successful (a decrease in bacterial cell counts
over 4.5 log CFU/mL by day 11) and cured 94% of the ani-
malswhereasthestandarddoseofdaptomycin(6mg/kg/day)
combined with rifampicin cured only two-thirds although
being similarly bactericidal when compared to the high-
dose daptomycin combined with rifampicin in vitro [53].
However, in an in vitro model of bioﬁlm with MRSA
susceptible to daptomycin, monotherapy with daptomycin
at a high dose (10mg/kg/day) was only minimally eﬀective
in diminishing the bioﬁlm cell counts within 72 h whereas
the addition of rifampicin enhanced the bactericidal activity
of daptomycin against bacteria in bioﬁlm [54].
The reason for the discrepancy in rifampicin action
among the results obtained in animal models of IE and
foreign-body infection is not clear. Recently, Olson et al.
proposed that rifampicin exerts the main bactericidal action
on a bioﬁlm while anti-staphylococcal antibiotics in the
combination with rifampicin only prevent the outgrowth
of rifampicin-resistant mutants which are known to emerge
frequently and in high numbers during monotherapy with
rifampicin in a laboratory setting [55].
5.2. Combinations of Daptomycin and Beta-Lactams. Com-
binations of daptomycin with beta-lactams have a basis in
an observation that in some cases MRSA, which develops
a diminished susceptibility to vancomycin or daptomycin,
becomes more susceptible to oxacillin, a so-called “see-saw”
eﬀect [56]. An example of such pathogen is MDR S. aureus
which becomes non-susceptible to daptomycin.
Various combinations have been tested in in vitro and
animal models, most commonly daptomycin combined with
a beta-lactam at a fraction of its MIC.
In in vitro time-kill experiments with MRSA susceptible
to daptomycin, synergy was found between daptomycin
at 0.5 MIC and 32mg/L oxacillin (oxacillin MIC for the
majority of tested strains ≥256mg/l). Aminopenicillins,
such as ampicillin, showed synergy at even lower con-
centrations (2–8mg/l ampicillin in a combination with
ampicillin/sulbactam) [57].
Similarly, addition of subtherapeutic levels of beta-
lactams to daptomycin delayed or prevented the emergence
of diminished susceptibility to daptomycin in in vitro selec-
tion studies performed on four homogenously daptomycin
susceptible MRSA which were also vancomycin-susceptible
(VSSA) and two heterogeneously daptomycin susceptible
and methicillin-resistant GISA strains. The MICs increased
2–4 times over the baseline in case of MRSA and only two-
fold in case of GISA [58], which is substantially less than
that seen after several passages of S. aureus in subinhibitory
concentrations of daptomycin alone [12, 16, 17]. The eﬀect
was the most pronounced in case of aminopenicillins, such
as ampicillin or amoxicillin/clavulanic acid [58].
Interestingly, in an in vitro pharmacodynamic model of
IE with simulated endocardial vegetations, the combination
of daptomycin 6mg/kg/day with cefepime 2g bid was
superior to daptomycin monotherapy in eradication of
MRSA/VSSA but not of MRSA/hVISA [59]. Both strains
were heterogeneously non-susceptible to daptomycin with
the former having two-fold higher MIC than the latter.
In in vitro time-kill assays using clinical strains of S.
aureus which developed non-susceptibility during treatment
(daptomycin MIC 2–4 mg/L) and one in vitro selected non-
susceptible strain (MIC 8mg/L), treatment with a combi-
nation of daptomycin and oxacillin at 0.25MIC showed
modest increase of in vitro oxacillin bactericidal activity
within 4–6 hours (1-2 log CFU/mL decrease in cell counts).
An in vivo study of a rabbit model of aortic IE was then6 Chemotherapy Research and Practice
Table 3: In vitro synergy of antibiotic combinations.
Method Strain Combination Observation Ref.
Etest and time-kill study hGISA/MSSA
Daptomycin with
vancomycin,
gentamicin, rifampin,
linezolid,
quinupristin/
dalfopristin,
ampicilin-sulbactam
Etest: additive eﬀect with daptomycin +
vancomycin and daptomycin + gentamycin,
other combinations with daptomycin
indiﬀerent
Time-kill study: additive eﬀect with
daptomycin + gentamycin, other
combinations with daptomycin indiﬀerent
[40]
Etest and time-kill study GISA/MRSA
Daptomycin with
vancomycin,
gentamicin, rifampin,
linezolid,
quinopristine/
dalfopristine,
ampicilin-sulbactam
Etest: additive eﬀect only with daptomycin
+ gentamycin, other combinationswith
daptomycin indiﬀerent
Time-kill study: indiﬀerence
[40]
Time-kill study MRSA Daptomycin +
gentamicin Synergy in all three strains [41]
Time-kill study MRSA Daptomycin +
rifampin
Antagonism in one strain and indiﬀerence
in two other strains [41]
Time-kill study MRSA
Daptomycin at 0.0625
MIC to 2 MIC +
oxacillin or
ampicillin- sulbactam
Synergy of daptomycin at 0.5 MIC +
oxacillin 32mg/L or ampicillin-sulbactam
2–8mg/L (ampicillin)
[57]
In vitro model of bioﬁlm MSSA
Daptomycin
10mg/kg/d +
clarithromycin
250mg q12h
Sustained bactericidal activity against
planctonic and bioﬁlm bacteria [54]
In vitro model of bioﬁlm MRSA
Daptomycin
10mg/kg/d +
rifampin at 600mg
q24h
Sustained bactericidal activity against
planctonic and bioﬁlm bacteria [54]
In vitro selection for
resistance
MRSA and
GISA
Daptomycin + 0.25
MIC ampicillin,
amoxicillin-clavulanic
acid, gentamicin,
rifampin
Combination with ampicillin,
amoxicillin-clavulanicacid
delayed/prevented occurrence of
non-susceptibility; rifampin delayed
non-susceptibility
[58]
Checkerboard method MRSA, MSSA
Daptomycin +
rifampicin,
moxiﬂoxacin or
fusidic acid
Daptomycin + fusidic acid: antagonismin
one MSSA strain reported [68]
MRSA: meticillin-resistantS.aureus; MSSA:meticillin-susceptibleS.aureus; GISA:glycopeptide-intermediateS.aureus; hGISA:heteroresistantglycopeptide-
intermediate S. aureus; MIC: minimal inhibitory concentration (mg/L).
performed using initial daptomycin susceptible and non-
susceptible clinical MRSA isolates. An increased bactericidal
eﬀectofthecombinationonthedaptomycinnon-susceptible
S. aureus strains was established; it was more pronounced in
vivo than in vitro. For the daptomycin-susceptible parental
strains, the combination treatment with beta-lactams was
not studied because daptomycin alone was found to be
suﬃciently bactericidal to cure the infection [56]. In spite
of the observed “see-saw” eﬀect (increased susceptibility to
oxacillin) in daptomycin non-susceptible strains oxacillin
monotherapy was not successful. All examined strains
retained mecA gene.
5.3. Combinations of Daptomycin with Bacteriostatic Antibi-
otics. A somewhat unusual combination of daptomycin and
TMP-SMX was studied in an in vitro pharmacodynamic
model of IE with simulated endocardial vegetations. The
TMP-SMX monotherapy was found inferior to the stan-
dard treatment of S. aureus IE [60]. The combination of
daptomycin at 6mg/kg/day and TMP-SMX at 160/800mg
bid was more rapidly bactericidal against daptomycin non-
susceptible strains of S. aureus than daptomycin alone [59].
The eﬃcacy of combination of clarithromycin and a
beta-lactam or vancomycin for eradication of S. aureus
bioﬁlms has already been demonstrated [61]. A similar
increase in bactericidal activity was observed in an in vitro
model of bioﬁlm using an MSSA strain. The combination
of daptomycin 10mg/kg/day and clarithromycin 250mg bid
was more eﬀective in eradication of bacteria in the bioﬁlm
than daptomycin alone [53].Chemotherapy Research and Practice 7
The mechanism behind the eﬃcacy of some of the
unusual combinations of antibiotics presented in this review
is not clear. A concept of a mutant prevention concentration
and mutant selection window hypothesis was proposed a
decadeago [62]. Mutant preventionconcentrationis deﬁned
as the minimal concentration of antibiotic at which no
single-step resistant mutants are recovered on agar plates
when plated at high inoculum (>1010 cells) [62]w h i l e
mutant selection window denotes a window between MIC99
and mutant prevention concentration in which resistant
mutants are enriched (MIC99/mutant prevention concentra-
tion) [63]. It is thought to represent the MICs of susceptible
and single-step resistant mutants. Both parameters are agent
and bacterial-strain dependent. Mutant selection window is
in some cases small with mutant prevention concentration
wellbelowtheclinicallyachievableantibioticconcentrations,
such as those of penicillin in case of MSSA. On the other
hand, mutant selection window of rifampicin for MSSA is
very broad (160,000) with mutant prevention concentration
of 480mg/L [63] which is far too high for clinical use. This
may explain the high resistance observed in the laboratory.
Combined treatment with two or more antibiotics may
have a lower mutant prevention concentration, since two
or more concomitant resistance mutations are necessary for
growth; thus, reaching concentrations of antibiotics that
exceed mutant prevention concentration is then feasible in a
clinicalsetting [63].Mutantselection windowhypothesishas
been conﬁrmed for daptomycin in vitro,w h e r et h em u t a n t
selection window is about2–5 with clinically achievable con-
centrations well above the mutant prevention concentration
with a currently highest approved daily dose of 6mg/kg
[64, 65]. Nevertheless, with the high protein binding of dap-
tomycin [4], the observed developmentof non-susceptibility
in vitro and in clinical cases at a dose of 6mg/kg/daysuggests
that the eﬀective free drug concentrations are lower (as
much as 90%) and that mutant prevention concentration
is not reached. This speculation is further strengthened by
the success of high doses of daptomycin (10mg/kg/day),
which are, even so, not approved by regulatory agencies
for clinical use. A combination of daptomycin with other
antibiotics may lower the mutant prevention concentration
as has already been described for tobramycin-rifampicin
combination [63].
6.Conclusionsand FutureOutlook
We have discussed combinations of daptomycin with other
antibiotics, a new therapeutic strategy for treatment of
complicated infections with S. aureus. Classical combination
of daptomycin with rifampicin seems to be eﬀective only for
foreign-body infections while data for IE is somewhat con-
tradictory. Combinations of daptomycin with beta-lactams,
TMP-SMX, or clarithromycin provide a fresh strategy in
combating infections with MDR S. aureus; the value of the
new approaches is supported by the ﬁndings of in vitro and
in vivo studies but is yet to be assessed and proven in clinical
settings.
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